15-12G - Finch Therapeutics Group, Inc. (0001733257) (Filer)

EFFECT - Finch Therapeutics Group, Inc. (0001733257) (Filer)

S-8 POS - Finch Therapeutics Group, Inc. (0001733257) (Filer)

POS AM - Finch Therapeutics Group, Inc. (0001733257) (Filer)

S-8 POS - Finch Therapeutics Group, Inc. (0001733257) (Filer)

S-8 POS - Finch Therapeutics Group, Inc. (0001733257) (Filer)

25 - Finch Therapeutics Group, Inc. (0001733257) (Filer)

8-K - Finch Therapeutics Group, Inc. (0001733257) (Filer)

10-Q - Finch Therapeutics Group, Inc. (0001733257) (Filer)

8-K - Finch Therapeutics Group, Inc. (0001733257) (Filer)

FDA lifted clinical hold on IND for CP101Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022$15 million drawn from new $55 million term debt facility Anticipated cash runway into Q2 2024Corporate update call today at 8am ET SOMERVILLE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. "Finch made several important

SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced it will host a conference call and live webcast on Monday, May 16, 2022 at 8:00am ET to discuss updates to its development programs and other business highlights. The conference call can be accessed by dialing (833) 649-1186 (domestic) or (270) 823-1080 (international) and entering conference ID 8451806. The live webcast can be accessed by visiting the ‘Investors & News' section of

H.C. Wainwright initiated coverage of Finch Therapeutics with a rating of Buy and set a new price target of $17.00

Jefferies initiated coverage of Finch Therapeutics with a rating of Buy and set a new price target of $29.00

Evercore ISI initiated coverage of Finch Therapeutics with a rating of Outperform and set a new price target of $34.00

BofA Securities initiated coverage of Finch Therapeutics with a rating of Buy and set a new price target of $25.00

BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (NASDAQ:FNCH) ("Finch" or the "Company"), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has provided notification to The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Global Select Market. Finch expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of its Common Stock on or about October 31, 2024. The removal of the Common Stock from Nas

BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced it will effect a one-for-30 reverse stock split of its issued and outstanding common stock. Finch stockholders approved an amendment to its Amended and Restated Certificate of Incorporation to effect the reverse stock split at Finch's Annual Meeting of Stockholders held on June 8, 2023. The reverse stock split is intended to increase the per share trading price of Finch's common stock to enable Finch to satisfy the minimum price requirement for

SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates. "Finch has continued to execute on its strategy to advance its novel microbiome technology through partnerships and collaborations, highlighted by the recent investigator-sponsored clinical trial agreement with Brigham and Women's Hospital to evaluate CP101 for the treatment of ulcerative colitis and an amended license agreement with the University of Minnesota," said

Matthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO effective May 15 Lance Thibault, Managing Director of Danforth Advisors, to serve as Chief Financial Officer effective May 16, 2023; Marc Blaustein to complete his time as Chief Operating Officer and principal financial officer effective May 15 SOMERVILLE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, toda

SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has entered into a clinical trial agreement with Brigham and Women's Hospital for the evaluation of CP101, a Complete Consortia microbiome therapeutic, in ulcerative colitis. The Company also announced updates to its license agreement with the University of Minnesota. Under the clinical trial agreement, Brigham and Women's Hospital will conduct an investigator-sponsored trial that is designed to compare two doses of CP101 i

SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported fourth quarter and full year 2022 financial results and provided business updates. "We believe that Finch has made significant progress towards restructuring the business to maximize value for shareholders through our robust intellectual property estate, including by continuing to support the advancement of our microbiome technology through partnerships and collaborations," said Mark Smith, PhD, Chief Executive Officer of Finch Ther

SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the "Company," "Finch," or "Finch Therapeutics") (NASDAQ:FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of its intellectual property estate and other assets. This decision follows an assessment by Finch's management team and board of directors of several factors, including the Company's outlook for securing additional capital or partnerships to help fund the CP101 program through important milestones, slower than anticipated enrollment in the PRISM4 trial, the harmful impact of ongoing unauthoriz

Patient dosing underway in PRISM4 Phase 3 trial of CP101 in recurrent CDITopline PRISM4 data anticipated in H1 2024 Anticipated cash runway into Q2 2024 SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today provided corporate updates and reported financial results for the third quarter ended September 30, 2022. "We are pleased with the tremendous progress our team has made recently to advance the development of our lead program, with patient dos

SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that the company will present at the following investor conferences: Jefferies London Healthcare ConferenceWednesday, November 16, 2022 at 10:55 am GMTCorporate presentation by Howard Franklin, MD, MBA, Chief Medical Officer Evercore ISI HealthCONx ConferenceThursday, December 1, 2022 at 11:20 am ETFireside chat with Mark Smith, PhD, Chief Executive Officer Live webcasts of both ev

SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced the presentation of biomarker data from PRISM-EXT, a Phase 2 open-label trial of CP101 in recurrent C. difficile infection (CDI), at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, being held October 21-26, 2022 in Charlotte, NC. Finch also announced today that the company has proceeded with patient dosing in PRISM4, a Phase 3 trial of CP101 for the prev

SC 13G - Finch Therapeutics Group, Inc. (0001733257) (Subject)

SC 13G - Finch Therapeutics Group, Inc. (0001733257) (Subject)

SC 13G - Finch Therapeutics Group, Inc. (0001733257) (Subject)

SC 13D - Finch Therapeutics Group, Inc. (0001733257) (Subject)

SC 13D - Finch Therapeutics Group, Inc. (0001733257) (Subject)

SC 13G - Finch Therapeutics Group, Inc. (0001733257) (Subject)

4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)

4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)

4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)

4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)

4/A - Finch Therapeutics Group, Inc. (0001733257) (Issuer)

4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)

4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)

4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)

4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)

4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)

SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates. "Finch has continued to execute on its strategy to advance its novel microbiome technology through partnerships and collaborations, highlighted by the recent investigator-sponsored clinical trial agreement with Brigham and Women's Hospital to evaluate CP101 for the treatment of ulcerative colitis and an amended license agreement with the University of Minnesota," said

Matthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO effective May 15 Lance Thibault, Managing Director of Danforth Advisors, to serve as Chief Financial Officer effective May 16, 2023; Marc Blaustein to complete his time as Chief Operating Officer and principal financial officer effective May 15 SOMERVILLE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, toda

SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today reported fourth quarter and full year 2021 financial results and provided business updates. "Finch achieved many significant milestones in 2021, including new clinical data readouts that support our lead product candidate, CP101, for the prevention of recurrent C. difficile infection and the advancement of our TAK-524 ulcerative colitis development program to Takeda for further development. F

Bryan Gillis, MBA, appointed Chief Technology OfficerAlka Batycky, PhD, appointed Chief Development OfficerHoward Franklin, MD, MBA, appointed Senior Vice President, Late-Stage Development and GI Therapeutic Area Lead SOMERVILLE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced the appointment of Bryan Gillis, MBA, to Chief Technology Officer, Alka Batycky, PhD, to Chief Development Officer, and Howard Franklin, MD, MBA, to Senior Vice Preside

SOMERVILLE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Samuel Allen (Al) Hamood has joined Finch's Board of Directors. Mr. Hamood is an accomplished executive with over 30 years of experience in finance, business development, corporate strategy, and M&A across several global industry sectors. "Through the course of his career, Al has been instrumental in developing and driving growth strategies and translating those strategies into

SOMERVILLE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced the appointment of Marc Blaustein as Chief Operating Officer. Mr. Blaustein is a seasoned biopharmaceutical executive with more than 20 years of experience building and leading companies and critical business functions including operations, business development, program management, and manufacturing. "I am delighted to welcome Marc to the Finch team at a time when we are positioned

Takeda to accelerate leadership role in advancing FIN-524/TAK-524 ulcerative colitis development programTopline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in open label PRISM-EXT trial expected in H2 2021Continued progress advancing development programs, with clinical data across multiple programs anticipated in 2022  SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today reported financial results for

SOMERVILLE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Susan E. Graf has joined Finch's Board of Directors and will serve as Chair of the Audit Committee. Ms. Graf is an accomplished biopharma executive with more than 25 years of experience spanning corporate strategy, finance, business development, M&A, and the development and commercialization of biopharmaceuticals. "With Finch's recent IPO, strong Phase 2 data from their lead can

https://register.epo.org/application?number=EP18843863

Shares of Teledyne Technologies Incorporated (NYSE:TDY) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter financial results and cut FY24 adjusted EPS guidance. Teledyne Technologies posted adjusted earnings of $4.55 per share, missing market estimates of $4.63 per share. The company's quarterly sales came in at $1.35 billion versus expectations of $1.40 billion, according to data from Benzinga Pro. Teledyne Technologies shares dipped 9.3% to $369.16 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSE) gained 136% to $0.3570. BranchOu

Shares of The Travelers Companies, Inc. (NYSE:TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' expectations. Core income per share reached $4.69 from $4.11 a year ago, missing the $4.90 consensus forecast. Net income per share rose to $4.80 from $4.13 a year earlier. Travelers shares dipped 8.1% to $205.03 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers INVO Bioscience, Inc. (NASDAQ:INVO) shares shot up 256% to $2.78 after the company reported a year-over-year increase in fourth-quarter revenue results and said it remains on track to reach its goa

Gainers INVO Bioscience (NASDAQ:INVO) stock rose 275.0% to $2.85 during Wednesday's regular session. The market value of their outstanding shares is at $7.4 million. As per the news, the Q4 earnings report came out yesterday. Vanda Pharma (NASDAQ:VNDA) stock moved upwards by 33.33% to $5.4. The company's market cap stands at $310.7 million. Galera Therapeutics (NASDAQ:GRTX) shares rose 27.76% to $0.22. The company's market cap stands at $11.8 million. SINTX Techs (NASDAQ:SINT) shares increased by 27.51% to $0.03. The company's market cap stands at $3.5 million. Viracta Therapeutics (NASDAQ:VIRX) stock moved upwards by 27.51% to $0.91. The company's market cap stands at $35.7 million. R

Gainers Qilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. The company's market cap stands at $40.7 million. Allarity Therapeutics (NASDAQ:ALLR) stock rose 18.09% to $2.48. The market value of their outstanding shares is at $1.1 million. Galecto (NASDAQ:GLTO) stock increased by 5.58% to $0.72. The company's market cap stands at $19.4 million. Finch Therapeutics Gr (NASDAQ:FNCH) shares increased by 5.28% to $2.19. The company's market cap stands at $3.5 million. CNS Pharma (NASDAQ:CNSP) stock rose 4.97% to $0.26. The market value of their outstanding shares is at $2.7 million. Cormedix (NASDAQ:CRMD) shares rose 4.96% to $6.13. Th

Finch Therapeutics Gr (NASDAQ:FNCH) reported quarterly losses of $(1.89) per share. This is a 88.75 percent increase over losses of $(16.80) per share from the same period last year.

Shares of Asana, Inc. (NYSE:ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. Asana reported quarterly losses of 4 cents per share which beat the analyst consensus estimate of losses of 10 cents by 60%. Quarterly sales came in at $171.1 million, beating the analyst consensus estimate of $167.676 million by 2.04%. The company expects fiscal year 2025 adjusted losses of between 22 cents and 19 cents per share, versus the losses of 22 cents estimate and fiscal year revenues of between $716 million and $722 million, versus the $724.75 estimate. Asana shares dipped 11% to $16.72 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers

Gainers Regulus Therapeutics (NASDAQ:RGLS) stock moved upwards by 84.8% to $2.55 during Tuesday's pre-market session. The company's market cap stands at $51.5 million. Assure Hldgs (NASDAQ:IONM) stock increased by 73.02% to $0.59. The market value of their outstanding shares is at $3.9 million. Telomir Pharmaceuticals (NASDAQ:TELO) shares increased by 24.89% to $8.58. The market value of their outstanding shares is at $262.6 million. Bioventus (NASDAQ:BVS) shares increased by 16.0% to $6.16. The market value of their outstanding shares is at $387.8 million. The company's, Q4 earnings came out today. Genelux (NASDAQ:GNLX) stock increased by 14.79% to $7.45. The company's market cap stand

Shares of Oracle Corporation (NYSE:ORCL) rose sharply in today’s pre-market trading after the company reported upbeat earnings for its fiscal third quarter. Oracle’s third-quarter revenue increased 7% year-over-year to $13.3 billion, which missed the consensus estimate of $13.306 billion, according to Benzinga Pro. The company reported quarterly earnings of $1.41 per share, which beat average estimates of $1.38 per share. Oracle shares jumped 13.4% to $129.46 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Singularity Future Technology Ltd. (NASDAQ:SGLY) gained 88.6% to $5.94 in pre-market trading after gaining over 6% on Monday. Nukkleus Inc.

Finch Therapeutics Gr (NASDAQ:FNCH) reported quarterly losses of $(1.51) per share. This is a 94.05 percent increase over losses of $(25.38) per share from the same period last year.